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Summary 
A unique mRNA produced in leukemic cells from a t(15; 
17) acute promyelocytic leukemia (APL) patient en- 
codes a fusion protein between the retinoic acid recep- 
tor a (RARa) and a myeloid gene product called PML. 
PML contains a cysteine-rich region present in a new 
family of apparent DNA-binding proteins that includes 
a regulator of the interleukin-2 receptor gene (Rpt-1) 
and the recombination-activating gene product (RAG-l). 
Accordingly, PML may represent a novel transcription 
factor or recombinase. The aberrant PML-RAR fusion 
product, while typically retinoic acid responsive, dis- 
plays both cell type- and promoter-specific differ- 
ences from the wild-type RARa. Because patients with 
APL can be Induced into remission with high dose RA 
therapy, we propose that the nonliganded PML-RAR 
protein is a new class of dominant negative oncogene 
product. Treatment with RA would not only relieve this 
inhibition, but the activated PML-RAR protein may ac- 
tually promote myelocyte differentiation. 
Introduction 
Karyotypic changes, including chromosomal transloca- 
tion, are consistently associated with cancer (Mitelman, 
1988). Specific changes, like those associated with bcr- 
abl, lead to the generation of fusion alleles and may be 
associated with initiation of cancer. In cases of acute leu- 
kemias, which represent clonal expansion of hematopoi- 
etic cells at certain developmental stages, genes located 
at the site of translocation may become activated to en- 
code an oncogenic protein that represents the etiologic 
agent of the disease. 
While chromosomal rearrangements are frequent hall- 
marks of malignant cells, the balanced t(l5;17) (q22;ql2- 
21) translocation is exclusively associated with acute pro- 
myelocytic leukemia (APL), and it is often the only visible 
karyotypic aberration present (Mitelman, 1988). This 
translocation is detected in as many as 90% of APL pa- 
tients and has become the definitive marker for the disease 
(Rowley et al., 1977a, 1977b; Mitelman, 1988). The chro- 
mosome 17 breakpoint in APL was recently mapped to the 
retinoic acid receptor a gene (RARa) (de The et al., 1990a; 
Borrow et al., 1990; Longo et al., 1990) and the transloca- 
tion results in a fusion between RARa and a region on 
chromosome 15 referred to as my/ (de The et al., 1990a). 
my/ has been renamed PML (for “promyelocytes”). RAR is 
a member of the steroid/thyroid hormone receptor super- 
family and regulates gene expression by acting as a 
ligand-dependent transcription factor (Evans, 1988; Gi- 
guere et al., 1987; Petkovich et al., 1987). The ligand, 
retinoic acid (RA), triggers cellular differentiation in a wide 
variety of cultured cells and is a developmental regulator 
in vivo. RA promotes differentiation of the myeloid HL-60 
cell line to postmitotic granulocytes(Breitman et al., 1980) 
and the all-trans RA induces complete remission in APL 
patients(Huanget al., 1988;Chomienneet al., 1990; Miller 
et al., 1990; Warrell et al., 1991). These observationssug- 
gest that the translocation activates or produces a fusion 
protein that is hormone responsive. The administration of 
the high doses of RA to APL patients must overcome the 
oncogenic defect to restore myelocytic differentiation. 
We report here the isolation of PML-RAR fusion cDNAs 
from an APL patient as well as the corresponding wild-type 
PML and RARa cDNAs. Structural analysis reveals that 
the PML protein is a member of a newly recognized protein 
family that includes a variety of putative transcription fac- 
tors as well as the recombination-activating gene product 
(RAG-l) (Schatz et al., 1989). We show that the aberrant 
PML-RAR fusion product is RA responsive, although it 
displays both promoter- and cell-specific differences from 
the wild-type RARa. Our data support a model in which 
myeloid differentiation is blocked by the PML-RAR fusion 
product and this inhibition relieved by RA treatment. 
Results 
Identification of RARa-Associated Reciprocal 
Transcripts in APL 
To look for the presence of altered RARa transcripts, RNA 
was isolated from bone marrow of an APL patient whose 
leukemic cells contained the t(l5;17) translocation (Ben- 
nett et al., 1976). Figure 1 a shows the results of a Northern 
blot analysis of such APL RNA probed with human RARa 
cDNA, and for comparison we show RNA isolated from 
HeLa cells. Previous work (A. K. and R. M. E., unpublished 
data) has shown the presence of 2.8-3.6 kb RARa tran- 
scripts from HeLa cells. Both RNA samples give rise to two 
common bands corresponding to normal RARa transcripts 
(2.8 kb and 3.6 kb). In the APL patient sample, two addi- 
tional bands (3.2 kb and 4.0 kb) are found that could be 
transcripts of the fusion between the RARa gene and the 
translocation locus on chromosome 15. To examine the 
translocation products further, a cDNA library was con- 
structed from the patient mRNA. After a series of sequen- 
tial screenings (see Experimental Procedures), candidate 
cDNAs coding for RARa, PML-RAR, RAR-PML, and PML 
proteins were isolated. Restriction enzyme and sequenc- 
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Figure 1. A Novel RAR Fusion Product in a Patient with APL 
(a) Five micrograms of total bone marrow RNA from an APL patient 
and HeLa cell RNA was analyzed by Northern blotting, using the hu- 
man RARa cDNA as a probe. Two wild-type mRNAs of 2.6 and 3.6 kb 
(open arrows) as well as two additional bands of 3.2 and 4.0 kb (closed 
arrows) are seen on the patient RNA. 
(b) Schematic structures of RARa and PML-RAR cDNA. The open 
reading frames are shown as open boxes, and untranslated regions 
as lines. The fusion portion (encoding 394 amino acids) from the PML 
gene is dotted. Regions encoding the DNA-binding domains derived 
from RARa are in black. The RA-binding domain is marked as RA. The 
segment used for Northern blotting is also shown. 
(c) The nucleotide and predicted amino acid sequences around the 
fusion points are presented. The nucleotide sequence from RARa is 
bold and underlined. 
ing analyses revealed that the fusion occurs in the N-termi- 
nal portion of the RARa coding sequence (Figure 1 b). Fig- 
ure lc shows the nucleotide sequences and the predicted 
amino acid sequences surrounding these fusion points. 
Two reciprocal fusion cDNAs were formed along with the 
cDNAs derived from the normal alleles of the RARa and 
PML genes. In addition, two distinctive forms of both RARa 
and PML-RAR cDNAs were identified that differ in length 
in the 3’noncoding regions, reflecting the results from the 
Northern blot (Figure la). The clones with the longest 5’ 
regions were selected for sequence analysis. 
Structure of PML 
Figure 2a shows the nucleotide sequence and predicted 
amino acid sequence of the PML-1 cDNA. The PML-1 
cDNA (pPML-7) consists of 2155 nucleotides and has a 
long open reading frame with two potential translational 
initiation codons (ATG) in the 5’ end of the cDNA. There 
is no in-frame upstream stop codon. The 5’ ends of 22 
cDNAs coding for PML and PML-RAR were sequenced to 
identify the longest extension, suggesting that the clone 
in Figure 2a codes for a nearly full-length cDNA. While the 
nucleotide sequences surrounding the second initiation 
codon more closely resemble the consensus initiation se- 
quence (Kozak, 1987) more than 90% of translation in 
vertebrates starts from the first methionine (Kozak, 1987): 
we thus refer to the first ATG as the putative translational 
start site. The predicted PML-1 protein consists of 560 
amino acids, with a relative moleculMHar weight of 62,006. 
Computer-assisted analysis of the PML-1 protein se- 
quence shows that PML-1 contains four structurally inter- 
esting regions (Chou and Fasman, 1978), including a 
proline-rich N-terminus, a cysteine-rich portion, a poten- 
tially a-helical region, and a serine-rich C-terminus region 
(Figure 2b). There is no signal peptide sequence or a trans- 
membrane region, suggesting that PML-1 is an intracellu- 
lar protein. Furthermore, there is no obvious nuclear local- 
ization signal or ATP-binding sequence. 
The most striking sequence in PML is the cysteine-rich 
motif (amino acids 57-227) which can be divided into 
three clusters (Figure 3a). Data base searches that fo- 
cused on this cysteine-rich region identified 11 protein se- 
quences with almost perfect conservation of all cysteines 
in the first cluster (Doolittle, 1987; Freemont et al., 1991). 
In all 11 proteins, eight cysteines/histidines and one pro- 
line are conserved in the first cluster. This cluster is sum- 
marized as C-X-I-C-XIo_2,-C-X-H-X-F-C-X&-I-X~15-C-P-L-C, 
where the isoleucine (I), phenylalanine (F), and leucine (L) 
residues are highly conserved, but not invariant. Cysteine 
and histidine conservation is reminiscent of the zinc finger 
motif seen in several different classes of transcription fac- 
tors(Miller et al., 1985; Evans and Hollenberg, 1968; Berg, 
1990) although the domain here likely represents yet a 
new class. Of these 11 homologous proteins, several are 
putative DNA-binding proteins. Although the function of 
this specific cysteine-rich domain has yet to be clearly 
demonstrated, the ability of Mel-l 8 to bind to DNA-cellu- 
lose requires the presence of this motif (Tagawa et al., 
1990). The LMCV-2 protein binds Zn2+ (Salvato and Shi- 
momaye, 1989), supporting the possibility that the other 
members of this family may also chelate Zn’+. Among 
these 11 proteins, PML, Rpt-1, and Rfp share additional 
amino acid homology through a second cysteine cluster, 
suggesting that these three proteins may be more closely 
related. Rpt-1 is a potential transcription factor for the 
interleukin-2 receptor gene (Patarca et al., 1988) and Rfp 
is a proposed regulator for spermatogenesis (Takahashi et 
al., 1988). In thissecond cysteinecluster, seven cysteinesl 
histidines and one glutamic acid are conserved among 
these three proteins, while PML has a third cysteine cluster 
(located between amino acids 189 and 227). The spacing 









40 50 60 
P s P s Pi-PTERAPASEi-EFQFLRCQQC-QAEA 
AGCCCAGCCCCAGCCCCAGCCCTACAGAGCGAGCCCCCGCG 
70 80 90 
KC P K L L P c L H TLCSGCLEASGMQCP I C QA P 
CCAAGTGCCCGAAGCTGCTGCTTGTCTGCACACGCTGTGCTCA~ATGCCTGGAGGCGTC~GCATGCAGTGCCCCATCTGCCAGGCGC 
100 110 120 
WPLGADTPALDNVFFESLQRRLSVYRQIVD 
CCTGGCCCCTAGGTGCAGACACACCCGCCCTGGATAACGTTTGTGG 
130 140 150 
A Q A V C TRCKESADFWCFECEQLLCAKCFEA 
ATGCGCAGGCTGTGTGCACCCGCTGCAAAGAGTCGGCCGACTTCTGGTGCTTTGAGTGCGAGCAGCTCCTCTGCGCCAAGTGCTTCGAGG 
160 170 180 
HQWFLKHEARPLAELRNQSVREFLDGTRKT 
CACACCAGTGGTTCCTCAAGCACGAGGCCCGGCCCCTAGCAGAGCTGCGCAACCAGTCGGTGCGTGAGTTCCTGGACGGCACCCGCAAGA 
190 200 210 
N N I F C SNPNHRTPTLTSI YCRGCSKPLCCS 
CCAACAACATCTTCTGCTCCAACCCCAACCACCGCACCCCTACGCTGACCAGCATCTACTGCCGAGGATGTTCCAAGCCGCTGTGCTGCT 
220 230 240 
CAL L D S S H S E LKCDISAEI QQRQEELDAMT 
CGTGCGCGCTCCTTGACAGCAGCCACAGTGAGCTCAAGTGCGACATCAGCGCAGCATGA 
250 260 270 
QALQEQDSAFGAVHAQMHAAVGQLGRARAE 
CGCAGGCGCTGCAGGAGCAGATAGTGCCTTTGGCGCGGTGCGCGTGCCG 
290 290 300 
T E E L IRERVRQVVAHVRAQE R E L L E A V DAR 
AGACCGAGGAGCTGATCCGCGAGCGCGTGCGCCAGGTGGTAGCTCACGTGCGGCGCGC 
310 320 330 
Y Q R D Y E E MA S RLGRLDAVLQR IRTGSA L V Q 
GGTACCAGCGCGACTACGAGAGATGGCCAGTCGGCTGGGCCGCCTGGATGCTGTGCTGCAGCGCATCCGCATCCGCACG~CA~GCGCTGGTGC 
340 350 360 
R M K C Y A SDQEVLDMHGFLRQALCR L R Q E E P 
AGAGGATGAAGTGCTACGCCTCGGACCAGGAGGTGCTGGACATGCACGGTTTCCTGCGCCAGGCGCTCTGCCGCCTGCGCCAGGAGGAGGAGC 
370 390 390 
QSLQAAVRTDGFDEFKVRLQD L S S C i--T Q G K 
CCCAGAGCCTGCAAGCTGCCGTGCGCACCGATGGCTTCGACGAGTTCAAGGTGCGCCTGCAGGACCTCAGCTCTTGCATCACCCAGGGGA 
400 4113 430 _-_ .I- 
D A A V SKKASPEAASTPRDPI DVDLPEEAER 
AA~TGCAGCTGTATCCAAGAAAGCCAGCCCAGAGGCTGCCAGCACTCCCAGGGACCCTATTGACGTTGACCTGCCCGAGGAGGCAGAGA n 430 440 450 
VKAQVQALGLAEAQPMAVVQ SVPGAHPVPV 
GAGTGAAGGCCCAGGTTCAGGCCCTGGGGCTGGCTGAAGCCCAGCCTATGGCTGTGGTACAGTCAGTGCCCGGGGCACACACCCCGTGCCAG 
460 470 490 
YAFSIKGPSYGEDV S N T TTAQKRKCSQTQC 
TGTACGCCTTCTCCATCAAAGGCCCTTCCTATGGAGAGGATGTCTCCAATACAACGACAGCCCAGACAGGACAGACCCAGT 
490 500 510 
PRKVIKMESEEGKEARLARSSPEQPRP S T S 
GCCCCAGGAAGGTCATCAAGATGGAGTCTGAGGAGGGGAAGGAGGCAAGGTTGGCTCGGAGCTCCCCGGAGCAGCCCAGGCCCAGCACCT 
520 530 540 
K A V SPPHLDGPPSPRSPVIGSEVFLPNSNH 
CCAAGGCAGTCTCACCACCCCACCTGGATGGACCGCCTAGCCCCAGGAGCCCCGTCATAGGAAGTGAGGTCTTCCTGCCCAACAGCAACC 
550 560 































280 327 395 
1 57 228 I &-Zl 503 560 I , 
NH2 1 ProI Cys I a-Helices I I Ser COOH 
I I I I 
Figure 2. Nucleotide and Amino Acid Sequence of PML-7 cDNA Isolated from an APL Patient mRNA 
(a) The triangle represents the fusion point seen in PML-RAR. A potential polyadenylation signal is underlined, Both AT& are shown in bold type 
(nucleotides 81-83 and 147-149). 
(b) Schematic structure of the PML-1 protein. The encoded protein contains four regions of interesting structure. They are denoted as follows: Pro, 
proline-rich region; Cys, cysteine-rich region; a-Helices, a helix-rich region; Ser, C-terminus region where several serines are surrounded by 
prolines. The triangle shows the fusion point seen in PML-RAF?. L-Z shows the position of a putative leucine zipper. The numbers above the boxes 




<------------------------ cluster 1 -----------------------> 
PML ( 54)FLRCQQCQ------AEAKCPK----------LLPCLET~SGCLEAS---------GM~ICQAPWPLGADTPA- 
RFP ( 13)ETTCPVCL------QYFAEPM----------MLDCGENICCACLARCWGTAET---NVS~Q~ETFPQRHMRPNR 
RPT-1 ( 12)EVTCPICL------ELLKEPV----------SADCNESFCRACITLNYESNRNTDGKGNCPVCRGNLRPNL 
MEL-18 ( lS)HLMCALCG------GYFIDAT---------TIVECLBSFCVQ 
RING1 ELMCPICL------DMLKNTM---------TTKECLWFCSKK 
RAG-1 (290)SISCQICE------HILADPV----------ETNCKBVFCYP 
PAD18 ( 25)LLRCHICK------DFLKVPV----------LTPCGETFCSLCIRTHLNN------OPN~LCLFE 
IEllO (113)GDVCAVCT------DEIAPHL-------RCDTFPCMBRFC~P~KTWMQL------~NT~L~AK 
VZ61 ( ~~)DNTCTICM------STVSDLG---------KTMPCLEDFCFVCI~WTST------SV~LCRCP 
CG30 ( 5)KLQCNICFSVAEIKNYFLQPIDRLTIIPVLELDTCKEQ~SMCIRKIRKRK-----KVP~LCRVE 











<----------- Cluster 11 ----------> 
PML (104)-LDNVFFESLQRRLSVYRQIVDAQAVCTRCKESADFWCFECEQLLCAKCFEA--EQWFLKEEARPLAELRNQSVliE (176) 
RFP ( 7O)HLAPrVTQLVKQLRTERPSGPGGEMGVCEKBREPLKLYCEEDQMPICWCDRSREBRG---ESVLPLEE-AVEGFKE (141) 
RPT-1 ( 72)HVANIVERLKGFKS-IP-EEEQKVNICAQBGEKLRLFCRKDM~I~LCERSQE~G---~QTALIEE-VDQEY~ (141) 
<----------- Cluster 111 -------------> 
PML (177)FLDGTRKTNNIFCSNPNBRTPTLTSIYGRGCSKPLaeSCAELKC (.227) 
b 
* * * * * 
PML (279)IRERVRQYVAHYRAQERELLEAVDBRYQRaYEEMASRLG~YLQRIR (327) 
Fra-1 (124)CRN~ELTDFLQA-ETPKLEDEK~GLQREIEELQKQKERLEL~LEAHE (171) 
c-fos (154)CRNRRJiELTDTLQA-ETRQLEDEKSALQTEIANLLKEKEKLEF~LAAHE (201) 
FosB (172)CRNItRRELTDRLQA-ETPQLEEEKAELESEIAELQKEKERI&FYLVAHK (219) 
Figure 3. PML Shares Amino Acid Similarity to Proteins Containing Cysteine-Rich and Leucine Zipper Motifs 
(a) Amino acid alignment of proteins with novel cysteine-rich motif. Three cysteine clusters are shown by arrows. Conserved amino acids, including 
cysteineslhistidines, are denoted in bold type. Dashes represent gaps in amino acid alignment. The numbers represent the position of the first and 
the last amino acids in the respective protein sequences. The protein sequences are cited as follows: Rfp, Takahashi et al. (1966); Rpt-1, Patarca 
et al. (1966); Mel-19 Tagawa et al. (1990); RINGl, Freemont et al. (1991); RAG-l, Schatz et al. (1969); RAD16, Jones et al. (1966); IEllO, Perry 
et al. (1966); VZ61, Davison and Scott (1966); CG30, Thiem and Miller (1969); LCMV-2, Salvato and Shimomaye (1989). Cysteines and histidines 
in the third cluster are denoted in shadowed lettering. 
(b) Amino acid alignment of putative leucine zipper of PML and the leucine zippers of the Fos family. Sold type denotes the amino acids conserved 
in all four proteins. Underlining denotes the similar amino acids conserved in all four proteins. Dashes represent gaps in amino acid alignment. 
The numbers represent the position of the first and the last amino acids in their protein sequences. Asterisks show the position of conserved leucines 
in proteins of the Fos leucine zipper family. The proteins from the Fos family are cited as follows: Fra-1, Cohen and Curran (1988); c-Fos, Van 
Severen et al. (1983); FosB, Zerial et al. (1969). 
of cysteine and histidine in this third cluster resembles a 
CCHC box (Berg, 1990) seen in retroviral zinc fingers. 
This structure analysis suggest8 that PML-1 may bind DNA 
through its cysteine-rich domain and is thus a candidate 
transcription factor. 
It is noteworthy that this protein family includes the 
recombination-activating gene product (RAG-l) (Schatz et 
al., 1989) and RAD18, a yeast gene product that is involved 
in repair of UV-damaged DNA (Jones et al., 1988). 
Following the cysteine-rich region is a large segment 
that could form multiple a helices. A segment in this a 
helix-rich domain shows homology to the leucine zipper 
region of the Fos family (Cohen and Curran, 1988; Van 
Beveren et al., 1983; Zerial et al., 1989) (Figure 3b). Be- 
cause the leucine zipper mediates dimerization between 
Fos and Jun, the presence of this related sequence raises 
the possibility that PML or PML-RAR may be part of a 
homo- or heterodimer complex. 
The C-terminal region following the a-helical region in- 
cludes ten serines, five of which are surrounded by 
prolines. This type of motif is reminiscent of serine phos- 
phorylation sites and suggests that PML may be a phos- 
phoprotein and a substrate for serine/threonine protein 
kinases and/or phosphatases (Kemp and Pearson, 1990; 
R. Doolittle, personal communication). interestingly, this 
region is deleted in PML-RAR (see below). 
At the N-terminus 18 of the 48 residues are prolines. A 
proline-rich motif is part of the transcriptional activation 
domain of CTF (Mermod et al., 1989) and has also been 
noted in many other mammalian transcription factors 
(Mitchell and Tjian, 1989, and reference therein). In addi- 
tion, six of these prolines are adjacent to serine residues 
and may also represent candidate phosphorylation sites 
(see above). We also identified multiple forms of PML 
cDNAs, presumably produced by alternative splicing, 
which give rise to different sized proteins as analyzed by 
in vitro translation analysis (data not shown). 
The identification of the reciprocal fusion gene products 
strongly suggests that the PA& gene is located on chromo- 
some 15. This was confirmed by analyzing metaphase 
chromosome preparations by fluorescent in situ hybridiza- 
tion. Among 34 informative metaphase preparations, 48 
fluorescent hybridization signals were observed and 22 
(49%) were present on chromosome 15. Of the 22 hybrid- 
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Figure 4. The PML Gene Maps to Human Chromosome 15q22 
Mapping of the PML gene to chromosome 15q22 region by in situ 
hybridization using a biotin-labeled PML-7 cDNA as a probe. The idio- 
gram of chromosome 15 depicts the distribution of the fluorescent 
signals relative to known banding patterns of chromosome 15. 
ization events observed on chromosome 1511 were pres- 
ent at 15q22 (Figure 4) and correspond closely to the 
known site of translocation (Mitelman, 1988). 
Structure of the PML-RAR Fusion cDNA 
The PML-RAR cDNA (pPML-RAR) consists of 3036 nucle- 
otides and has an open reading frame that continues in 
frame from PA& to the RARa terminus (Figure 5). The 
predicted protein consists of 797amino acids, with a calcu- 
lated relative molecular mass of 89,281, and gives rise to 
a 90 kd product when tested by the in vitro transcription- 
translation system (data not shown). Using an RARa- 
specific antibody, the fusion protein can be detected in 
nuclear extracts of COS cells transfected with a PML-RAR 
cDNA expression vector(data not shown). The fusion point 
occurs between nucleotide 1249 and 1250 in the PML- 
RAR sequence (Figure 5) and produces a new codon for 
alanine at residue 395. The fusion PML-RAR protein sub- 
stitutes 394 amino acids from PML in place of the first 59 
amino acids from the N-terminus of RARa. 
If the PML-RAR fusion gene is a unique translocation 
product in all APL patients, the fusion mRNA should be 
diagnostic for the presence of leukemic cells. Accordingly, 
polymerase chain reaction (PCR) analysis with primers 
flanking the fusion point was used to characterize APL 
RNA described in Figure 1 and from an additional patient. 
Primers include a sense oligonucleotide from PML and 
an antisense oligonucleotide from RARa (Figure 6a and 
Experimental Procedures). A 439 bp product is predicted 
for APL patients with PML-RARa translocations. Figure 
6b shows the ethidium bromide staining of an agarose gel 
for the PCR product from two patient RNA samples. Each 
patient yielded a band of about 440 bp (Figure 6b, open 
arrow), while HeLa RNA gave no signal. The identity of 
the PCR products was confirmed by restriction enzyme 
analysis and verified the amplification (data not shown). 
Primers specific for RARa cDNA (Figure 6a and Experi- 
mental Procedures) yielded identical PCR products in all 
three RNAsamples(Figure6b, bottom). These resultscon- 
firm that the fusion transcript presented here is specific 
and common for these two APL patients. We have ana- 
lyzed additional APL cases using these same oligonucleo- 
tide primers, all but one showing the same result. The one 
exception showed a longer amplification product, indicat- 
ing that a translocation had occurred in the same genes 
but in adifferent position (W. H. M. and E. D., unpublished 
data). 
We also identified multiple forms of RAR-PML fusion 
cDNAs resulting from the reciprocally translocated allele. 
The detailed structures of these products are being deter- 
mined. Considering the overall structural feature of PML- 
RAR and RAR-PML fusion proteins and that PML-RAR 
contains the highly conserved domains from both gene 
products, PML-RAR represents the focus of the remain- 
der of our analyses here. 
PML-RAR Is a Transcription Activator 
To facilitate functional analysis, wild-type RARa and PML- 
RARcDNAs were transferred to the pCMX expression vec- 
tor (Umesono et al., 1991), creating pCMX RARa and 
pCMX PML-RAR, respectively. A deletion mutant (pCMX 
APML-RAR) that lacks the entire PML segment was also 
generated (see Experimental Procedures). The receptor 
expression vector was cotransfected with a set of CAT 
reporter plasmids based on a minimal SV40 promoter in 
which the enhancer was removed (ASV) and substituted 
with various RA response elements. The response ele- 
ments included TREp, which is a palindromic response 
element activated by high levels of thyroid hormone and 
RA receptors (Umesono et al., 1988), and f3RE, which is 
a natural element from the RARP gene and is responsive 
to low levels of RAR (Sucov et al., 1990; de The et al., 
1990b). These reporter vectors allow comparison of the 
transcriptional activities of the PML-RAR fusion receptor 
with that of transfected RARa and endogenous RAR. 
PML-RAR fusion constructs could transactivate RA re- 
sponse elements when treated with RA (Figure 7). Unex- 
pectedly, in CV-1 cells, the fusion receptor showed consti- 
tutive transactivation on both TREp and f3RE (Figure 7a). 
This transactivation was further enhanced by adding RA 
exogenously, resulting in about 2-fold greater induction. 
In contrast, the deletion mutant (pCMX APML-RAF?) failed 
to display the constitutive phenotype and is nearly identical 
to the wild-type RARa. This indicates that the constitutive 
activation property has resulted not from the truncation of 
the RARa N-terminus, but from the fusion with the PML 
gene product. 
To explore potential cell type variation, PML-RAR was 
expressed in avarietyof cell lines. In Hep G2 cells (human 
hepatocellular carcinoma) and K562 cells (human my- 
eloerythroblast leukemia), PML-RAR responded similarly 
as in CV-1 cells (data not shown). The PML-RAR fusion 
protein resulted in a high constitutive activation that was 






10 20 30 
PRPQQDPARPQEPTMPPPETPSEGRQPSPS 
CCGAGGCCCCAGCAGGACCCCGCCCGGCCCCAGGAGCCCACCATGCCTCCCCCCGAGACCCCCTCTG~GGCCGCCAGCCCAGCCCCAGC 
40 50 60 
PSPTERAPASEEEFQFLRCQQCQAEAKCPK 
CCCAGCCCTACAGAGCGAGCCCCCGCTTCGGAGGAGGAGTTCCAGTTTCTGCGCTGCCAGCMTGCCAGGCGGMGCCMGTGCCCGMG 
70 SO 90 
LLPCLHTLCSGCLEASGMQCPICQAPWPLG 
CTGCTGCCTTGTCTGCACACGCTGTGCTCAGGATGCCTGGAGGCGTCGGGCATGCAGTGCCCCATCTGCCAGGCGCCCTGGCCCCTAGGT 
100 110 120 
ADTPALDNVFFESLQRRLSVYRQIVDAQAV 
GCAGACACACCCGCCCTGGATAACGTCTTTTTCGAGAGTCTGCAGCGGCGCCTGTCGGTGTACCGGCAGATTGTGGATGCGCAGGCTGTG 
130 140 150 
CTRCKESADFWC FECEQLLCAKC FEAHQWF 
TGCACCCGCTGCAAAGAGTCGGCCGACTTCTGGTGCTTTGAGTGCGAGCAGCTCCTCTGCGCCMGTGCTTCGAGGCACACCAGTGGTTC 
160 170 180 
LKHEARPLAELRNQSVREFLDGTRKTNNIF 
CTCMGCACGAGGCCCGGCCCCTAGCAGAGCTGCGCMCCAGTCGGTGCGTGAGTTCCTGGACGGCACCCGCAAGACCMCMCATCTTC 
190 200 210 
C SNPNHRTPTLTS IYCRGCSKPLCCSCALL 
TGCTCCMCCCCMCCACCGCACCCCTACGCTGACCAGCATCTACTGCCGAGGATGTTCCMGCCGCTGTGCTGCTCGTGCGCGCTCCTT 
220 230 240 
D S S HSELKCDI SAEIQQRQE ELDAMTQALQ 
GACAGCAGCCACAGTGAGCTCMGTGCGACATCAGCGCAGAGATCCAGCAGCGACAGGAGGAGCTGGACGCCATGACGCAGGCGCTGCAG 
250 260 270 
E Q D SAFGAVHAQMHAAVGQL GRARAETEEL 
GAGCAGGATAGTGCCTTTGGCGCGGTTCACGCGCAGATGCACGCGGCCGTCGGCCAGCTGGGCCGCGCGCGTGCCGAGACCGAGGAGCTG 
280 290 300 
IRERVRQVVAHVRAQE RELLEAVDARYQRD 
ATCCGCGAGCGCGTGCGCCAGGTGGTAGCTCACGTGCGGGCTCAGGAGCGCGAGCTGCTGGAGGCTGTGGACGCGCGGTACCAGCGCGAC 
310 320 330 
YEEMAS RLGRLDAVLQRIRTGSALVQRMKC 
TACGAGGAGATGGCCAGTCGGCTGGGCCGCCTGGATGCTGTGCTGCAGCGCATCCGCACGGGCAGCGCGCTGGTGCAGAGGATGMGTGC 
340 350 360 
YASDQEV LDMHGFLRQALC RLRQEEPQSLQ 
TACGCCTCGGACCAGGAGGTGCTGGACATGCACGGTTTCCTGCGCCAGGCGCTCTGCCGCCTGCGCCAGGAGGAGCCCCAGAGCCTGCAA 
370 380 390 
AAVRTDGFDE FKVRLQDLS s c I pm+q-?YRTa T Q G K 
GCTGCCGTGCGCACCGATGGCTTCGACGAGTTCMGGTGCGCCTGCAGGACCTCAGCTCTTGCATCACCCAGGGGAAAGCCATTGAGACC 
400 410 420 A 
QSSSSEEIVPSPPSPPPLPRIYKPCFVCQD 
CAGAGCAGCAGTTCTGMGAGATAGTGCCCAGCCCTCCCTCGCCACCCCCTCTACCCCGCATCTACMGCCTTGCTTTGTCTGTCAGGAC 
430 440 450 
KSSGYHYGVSAC EGCKGFFRRS IQKNMVYT 
MGTCCTCAGGCTACCACTATGGGGTCAGCGCCTGTGAGGGCTGCAAGGGCTTCTTCCGCCGCAGCATCCAGMGAACATGGTGTACACG 
460 470 480 
CHRDKNCI I N K V T RNRCQYCRLQKCFEVGM 
TGTCACCGGGACMGRACTGCATCATCAACAAGGTGACCCGGRACCGCTGCCAGTACTGCCGACTGCAGMGTGCTTTG~GTGGGCATG 
490 500 510 
S K E S V R N D RNKKKKEVP KPECSESYTLTPE 
TCCAAGGAGTCTGTGAGAAACGACCG~CMG~GMG~GGAGGTGCCCMGCCCGAGTGCTCTGAGAGCTACACGCTGACGCCGGAG 
520 530 540 
VGELIEKVRKAHQETFPALCQLGKYTTNNS 
GTGGGGGAGCTCATTGAGAAGGTGCGC~GCGCACCAGGARACCTTCCCTGCCCTCTGCCAGCTGGGCMATACACTACGAACAACAGC 
55" 560 570 ___ 
SEQRVSLD IDLWDKFS ELSTKCII KTVEFA 
TCAGMCAACGTGTCTCTCTGGACATTGACCTCTGGGACMGTTCAGTGMCTCTCCACCMGTGCATCATTMGACTGTGGAGTTCGCC 
580 590 600 
K Q L PGFTTLTIADQ ITLLKAACLD ILILRI 
MGCAGCTGCCCGGCTTCACCACCCTCACCATCGCCGACCAGATCACCCTCCTCMGGCTGCCTGCCTGGACATCCTGATCCTGCGGATC 
610 620 630 
CTRYTP EQDTMT FSDGLTLNRTQMHNAGFG 
TGCACGCGGTACACGCCCGAGCAGGACACCATGACCTTCTCGGACGGGCTGACCCTGMCCGGACCCAGATGCACMCGCTGGCTTCGGC 
640 650 660 






















670 680 690 
LICGDRQDLEQPDRVDMLQEPLLEALKVYV 
CTCATCTGCGGAGACCGCCAGGACCTGGAGCAGCCGGACCGGGTGGACATGCTGCAGGAGCCGCTGCTGGAGGCGCT~GGTCTACGTG 2160 
7"" 710 720 .__ 
R K R R P S R P H M F P KMLMKITDLRSI SAKGAE 
CGGMGCGGAGGCCCAGCCGCCCCCACATGTTCCCCMGATGCTRATGAAGATTACTGACCTGCGAAGCATCAGCGCCMGGGGGCTGAG 
730 740 750 
RVITLKME IPGSMP PLIQEMLE NSEGLDTL 
CGGGTGATCACGCTGMGATGGAGATCCCGGGCTCCATGCCGCCTCTCATCCAGG~TGTTGGAGMCTCAGAGGGCCTGGACACTCTG 
760 770 780 
S G Q PGGGGRDG GGLAPP PGSCSP SLSPSSN 
AGCGGACAGCCGGGGGGTGGGGGGCGGGACGGGGGTGGCCTGGCCCCCCCGCCAGGCAGCTGTAGCCCCAGCCTCAGCCCCAGCTCCAAC 
790 








Figure 5. Nucleotide and Amino Acid Sequence of the PML-RAR cDNA Isolated from APL Patient mRNA 
















Figure 6. PCR Detection of PML-RAR Fusion Transcript 
(a) Schematic showing the primers used for PCR detection. Arrows 
represent the positions of primers used in PCR (see Experimental 
Procedures). Numbers represent the predicted size of PCR products. 
(b) Ethidium bromide staining of the PCR products. (Top) The open 
arrow shows the products of the PCR, using PML-RAF&specific prim- 
ers (see Experimental Procedures). The closed arrow shows unutilized 
primers. (Sottom) The products of the PCR with RARa-specific primers 
are shown (see Experimental Procedures). The negative image of the 
photograph is printed. 
eloid leukemia cell line HL-60, PML-RAR becomes fully 
ligand dependent (Figure 7b). Furthermore, in the absence 
of RA the fusion proteins actually suppress basal level 
transcription. Nonetheless, in this case, the RA-induced 
response is still P-fold greater than that of wild-type RARa 
(Figure 7b). 
The transactivational function of PML-RAR was as- 
sessed in two other promoter contexts. In one case, using 
a thymidine kinase promoter containing a TREp (Damm et 
al., 1969), both RARa and PML-RAR show comparable 
inductive profiles in CV-1 cells (Figure 7~). In another case 
the RA-responsive promoter from the RARp gene (Sucov 
et al., 1990) was used to monitor PML-RAR activity(Figure 
7d). In CV-1 cells with an RAR6 element, a fully hormone- 
dependent response was observed with RA. While consti- 
tutive activity was not seen, it was clear that PML-RAR 
displays a more effective activation profile than the wild- 
type RAR. Again, when the PML extension is deleted, the 
superinduction is also lost (Figure 7d). These data indicate 
significant cell type variation in the activation profiles of 
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ASV-TREp ASV-5RE TK-TREp RAW(P) 
Figure 7. Comparison of the Transactivation Abilities of RARa and 
PML-RAR 
The transactivation abilities of RARa and PML-RAR were monitored 
in the presence (hatched bars) or absence (solid bars) of 1 uM RA. An 
expression plasmid coding for the firefly luciferase (Control), RARa, 
PML-RAR,oradeletion mutantof PML-RAR(APML-RAR)wastested 
in various combinations with five different CAT reporters (AS/, ASV- 
TREp, ASV-6RE, TK-TREp, RARP(P)), in CV-1 cells (a, c, and d) or 
HL-60 cells (b). There is a significant increase in activation with PML- 
RAR compared with RARa. This increase is dependent on the pres- 
ence of the PML segment, since it is absent with APML-RAR. 
least as effective as wild-type RARa and generally is a 
more effective activator than wild-type RARa. 
Discussion 
Evidence is presented that the t(15;17) translocation in 
APL involves reciprocal fusions between the RARa gene 
on chromosome 17 (Mattei et al., 1968) and a gene (PML) 
encoding a novel putative DNA-binding protein. The trans- 
location is proposed to create an oncogene whose prod- 
uct, PML-RAR, is suggested to be a chimeric transcription 
factor. 
The creation of a chimeric transcription factor is reminis- 
cent of the translocation of t(1;19) in pre-B cell acute 
lymphocytic leukemia, which fuses a homeobox protein 
(Prl) with a helix-loop-helix protein (E2A) that is a known 
regulator of the K-immunoglobulin gene enhancer (Nourse 
et al., 1990; Kamps et al., 1990). PML is part of a newly 
Cell 
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recognized class of regulatory proteins that includes can- 
didate transcription factors such as Rpt-1 (Patarca et al., 
1988) (a regulator of the interleukin-2 receptor gene) and 
two potential oncoproteins, Rfp (Takahashi et al., 1988) 
and Mel-l 8 (Tagawa et al., 1990). This family also includes 
the products of the recombination-activating gene (RAG- 
I), which controls immunoglobulin gene rearrangement 
(Schatzet al., 1989), and RAD78, a yeast gene for postrep- 
lication repair of UV-damaged DNA (Jones et al., 1988). 
While perhaps serving different functions, these gene 
products are thought to bind to DNA, suggesting that the 
conserved cysteine cluster may encode this property. The 
total of eight cysteinelhistidine residues suggests that this 
region could coordinate two zinc ions, which would thus 
represent a novel class of DNA-binding finger (Berg, 
1990). 
The second cysteine cluster in PML contains seven cys- 
teinelhistidine residues and is similar to those of the Rfp 
and Rpt-1 proteins. The functional significance of this clus- 
ter is less clear. Finally, a third cluster (amino acids 189- 
227) containing cysteinelhistidine residues is currently 
unique to PML and represents yet a third potential region 
for zinc coordination and DNA binding. 
Within the potentially a-helical region in the center of 
PML is a segment (amino acids 280-327) with homology 
to the leucine zippers from c-Fos, FosB, and Fos-related 
antigen (Fra-1) (Van Beveren et al., 1983; Zerial et al., 
1989; Cohen and Curran, 1988). If analogous in function 
this would present a potential dimerization interface for 
PML. Regardless, the three cysteine clusters, as well as 
the candidate leucine zipper, are all present in the PML- 
RAR chimeric product and their properties are potentially 
important in transforming potential. In addition to the 
DNA-binding motifs, the N-terminus of PML contains 16 
prolines in the first 46 amino acids. Proline-rich sequences 
have previously been associated with transcription activa- 
tion domains in the CTF family of transcription factors 
(Mermod et al., 1989) and have also been found in the 
N-terminal portion of the El2 transcription factor (Murre et 
al., 1989). Together, these results support the proposal 










The PML-RAR fusion protein lacks the N-terminal 59 
amino acids of RARa but retains intact the DNA-binding 
and ligand-binding domains. The deleted N-terminal 59 
amino acids of RARa appear to have little function in trans- 
activation, as pCMX APML-RAR has properties similar to 
those of RARa (Figures 7a and 7d). The PML-RAR fusion 
protein creates a potentially bifunctional protein with multi- 
ple DNA-binding and transcriptional regulatory properties. 
Consistent with this suggestion, PML-RAR has altered 
transactivation properties relative to wild-type RARa (Fig- 
ure 7). Two conspicuous properties are its superinducible 
activity by RA and its suppression of basal activity in the 
absence of RA (Figure 7). 
In the accompanying paper an additional isoform of 
PML-RAR has been isolated from an APL patient. This 
additional isoform (PML-RAR(L)) includes 552 rather than 
394aminoacidsfrom the PMLprotein (deTheet al., 1991). 
In cotransfection using reporters and cells shown in Figure 
7, no significant differences were observed between these 
isoforms (data not shown). However, both isoforms showed 
unique transcriptional activities on a TK promoter carrying 
three tandem copies of the 8RE (TK-(8RE)J). Each fusion 
protein showed very weak transactivation properties com- 
pared with that of transfected wild-type RARa in Hep G2 
cells (Figure 8a). In this assay transactivation levels of both 
isoforms did not rise above the endogenous level, and in 
the case of PML-RAR(L), it displayed a mild suppressive 
phenotype. However, when tested on the RARP(5K) pro- 
moter both isoforms showed a net positive induction rela- 
tive to endogenous activity in Hep G2 cells. It is noteworthy 
that in CV-1 cells, PML-RAR is a better activator than 
RARa on the RARf3 promoter (Figure 7d). Finally in Figure 
8c, reducing the number of response elements from three 
to one (TK-9RE) reverts the neutral or suppressive pheno- 
type of PML-RAR into a positive activator. These lines of 
evidence clearly indicate that both isoforms show compa- 
rable altered transactivation phenotypes, which include 
cell-specific and promoter-specific variation. These pat- 
terns of variation are associated with the fused PML seg- 
ment, suggesting that PML-RAR interacts with transcrip- 
tion factors in a fashion distinct from RARa alone. 
Figure 8. Comparison of the Transactivation 
Abilities of PML-RAR lsoforms on Different 
Promotors 
An expression plasmid coding for RARa. PML- 
RAR, PML-RAR(L), or APML-RAR was tested 
on three different LUC reporters (TK-(~RE)s, 
RARf3(5K). or TK-6RE) in Hep 62 cells. The 
pCMX vector alone was used in control trans- 
fections. PML-RAR(L) is an isoform of PML- 
RAR and has 552 rather than 394 amino acids 
from the PML protein (see Figure 2a and text). 
The percent LUC activity is calculated relative 
to that of transfected RARa as 100%. Hatched 
bars and solid bars are as in the legend to 
Figure 7. 
TK-8RE 
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How might PML-RAR contribute to APL? While there 
are several possibilities, each must account for two clinical 
observations: greater than 90% of APL patients have t(15: 
17) suggesting that the mutant RAR allele is a new onco- 
gene; and patients with APLcan be induced into remission 
by high dose RA treatment (Huang et al., 1988; Cho- 
mienneet al., 1990; Milleret al., 1990; Warrell et al., 1991). 
The most parsimonious explanation is that PML-RAR acts 
to block or interfere with myelocyte differentiation. This 
idea has precedence with the v-ErbA oncoprotein that is 
thought to cause erythroleukemia by blocking the func- 
tions of its endogenous cellular counterpart, the thyroid 
hormone receptor (Damm et al., 1989; Zenke et al., 1990). 
According to this model, v-e&A and the PAM-RAR fusion 
gene could be thought of as dominant negative onco- 
genes. 
In one model, PML-RAR would function as an RAR an- 
tagonist and be insensitive to RA induction. Indeed, on the 
TK-(f3RE)a reporter PML-RAR is a poor transactivator and 
may suppress endogenous RAR activity. Furthermore, 
PML-RAR is frequently able to suppress basal activity of 
noninduced promoters(Figures7b, 8a, 8b, and 8c) relative 
to RARa, which generally enhances these effects. How- 
ever, support for this model is reduced by the observation 
that the PML-RAR fusion protein contains an intact RA 
ligand-binding domain and, in general, shows hormone 
responsiveness in most cell lines and promoters tested 
(Figures 7, 8b, and 8~). 
An alternative, but not exclusive, model is that PML- 
RAR functions as a dominant negative inhibitor of the en- 
dogenous PML activation pathway. It has previously been 
shown that heterologous transactivators fused to the 
ligand-binding domain of a steroid receptor become hor- 
mone dependent. Thus, ElA or GAL4 fused to the gluco- 
corticoid receptor show dexamethasone-dependent activ- 
ity (Picard et al., 1988; Hollenberg and Evans, 1988). 
Similarly, the transforming activity of the Myc protein be- 
comes estrogen dependent when fused to the estrogen 
receptor (Eilers et al., 1989), and the transcription factor 
CIEBP, which induces hepatocyte differentiation, becomes 
hormone dependent in this process when fused to the 
glucocorticoid receptor or estrogen receptor (Umex et al., 
1991). For PML-RAR we propose that the t(15;17) translo- 
cation places the PML product under the control of the 
RAR ligand-binding domain. Similar to v-ErbA, the fusion 
protein might block function of wild-type PML by forming 
nonproductive heterodimers or by blocking target DNA 
sites. Addition of RA would reverse this inhibition by trans- 
forming the receptor to an activated state. This model pro- 
vides a simple explanation as to why APL patients are 
amenable to RA treatment. A conclusive test for either 
model will require identifying PML-RAR target genes cru- 
cial for leukemogenesis. 
It is hoped that these studies will help to bring a sharper 
focus on the molecular defect in APL as well as provide 
some insights into both its diagnosis and treatment. First, 
as indicated in Figure 6b, it should be possible to use PCR 
as a definitive form of diagnosis and a means to monitor 
the progress of APL patients. Second, because the fusion 
occurs uniquely with RARa, it should be possible to identify 
therapeutic RA analogs that would be selective for this 
receptor subtype. Finally, this work should lead to a better 
understanding of the role of retinoids in normal myelocyte 
differentiation and the role of nuclear receptors in human 
disease. 
Experimental Procedures 
RNA Preparation and Northern Blotting 
Bone marrow cells from an APL patient were aspirated, and mononu- 
clear fractions were collected by Ficoll-Paque sedimentation (Phar- 
macia-LKB) (Miller et al., 1990). Total RNA was prepared from patient 
mononuclear fractions and HeLa cells by the guanidium thiocyanate 
method (Chirgwin et al., 1979). Northern blotting analysis was per- 
formed as described previously (Kakizuka et al., 1990; Mangelsdorf 
et al., 1990). The Pstl fragment covering nucleotides 538-l 156 from 
human RARa (Giguere et al., 1967) was used as hybridization probe. 
Patient cDNA Library Construction and Screening 
for PML-RAR, RAR-PML, PML, and RARa 
One microgram of poly(A)’ RNA was purified from 100 I.rg of total RNA 
from the mononuclear bone marrow cells of one APL patient, using 
oligo(dT)-Latex (Kuribayashi et al., 1968). Double-stranded cDNA was 
synthesized by the method of Gubler and Hoffman (1983) with minor 
modifications. After attachment of an EcoRI-Notl adaptor (Pharmacia- 
LKB), double-stranded cDNA was size fractionated by electrophoresis 
on a 0.6% agarose gel, and the cDNAs longer than 2 kb were ligated 
to a hZAP II vector (Stratagene). Approximately 5 x 1 O5 plaques were 
screened with the probe described above for the Northern blotting. 
The first screen gave more than 100 positives, of which 40 random 
clones were purified. The 40 clones could be classified into two major 
groups. One major group consisted of RARa and the other corres- 
ponded to PML-RAR. Each major group had a unique Kpnl site in the 
5’part of the cDNA. EcoRI-Kpnl fragments of about 700 bp and 1000 
bp were isolated from clone 2 (RARa) and clone 66 (PML-RAR), re- 
spectively. Half of the membrane filters used for initial screen were 
rehybridized with each of the EcoRI-Kpnl fragments. The probe from 
RARa and PML-RAR gave rise to 9 and 19 nonoverlapping clones, 
respectively. These clones identified cDNAs coding for RAR-PML and 
wild-type PML. Wild-type RARa (clone 2), PML-RAR (clone 66) and 
PML-7 (clone 124) were sequenced entirely. The amino acid sequence 
of RARa (clone 2) was identical to that published (Giguere et al., 1987). 
Chromosomal Assignment and Mapping of PML 
by In Situ Hybrldization 
PML-7 (clone 124) was labeled with biotin 1 I-dUTP (Enzo Biochemi- 
cals) using Escherichia coli DNA polymerase I (Maniatis et al., 1982). 
Metaphase chromosome preparations from phytohemagglutinin- 
stimulated and 5-bromodeoxyuridine-synchronized cultures of normal 
male lymphocytes (Zabel et al., 1983) were utilized as previously de- 
scribed (Neel et al., 1982; Jhanwar et al., 1983). The hybridization 
signal was detected by immunofluorescence using avidin-conjugated 
fluorescein isothiocyanate (FITC-avidin) and biotinylated anti-avidin 
using the in situ hybridization kit (ONCOR) as described (Pinkel et al., 
1986; Fan et al., 1990). 
Reverse TranscriptionlPCR Detection of the PML-RAR 
Fusion Gene 
One microgram of total RNA was converted to cDNA with 40 ng of 
random hexanucleotide (pd(N),, Pharmacia-LKB) and 200 U of 
RNAase H- Super Script reverse transcriptase (Bethesda Research 
Laboratories) in 20 pl of 50 mM Tris-HCI (pH 8.3) 75 mM KCI, 3 mM 
MgCI,, 10 mMdithiothreitol, and 500 PM of each.dNTP at 37OC for 1 
hr. Ten to 20 ng of cDNA was used for PCR amplification in 25 ul of 
67 mM Tris-HCI (pH 8.8) 16.6 mM (NH&SO,, 10 mM f3-mercaptetha- 
nol, 10% dimethylsufoxide, 2 mM MgCb, 250 KM of each dNTP, 1 uM 
of each primer, and 1.5 U of Taq polymerase (Cetus). Amplification 
was carried out for 35 cycles in an Eppendorf MicroCycler (1 min 
denaturation at 92OC, 2 min annealing at 55OC, 3 min elongation at 
72°C). One pair of primers (5’-GCG GTA CCA GCG CGA CTA CGA 
GGA GAT-3’ and 5’-GCG GCG GAA GAA GCC ClT GCA GCC CTC 
ACA GG-3’) was used for PML-RAR, and another pair (5’-ATG GCC 
Cdl 
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AGC AAC AGC AGC TCC TGC CCG ACA-3’ and 5’-GCG GCG GAA 
GAA GCC Cl7 GCA GCC CTC ACA GG-31 for RARa. 
Plasmid Constructions 
The EcoRl fragment from clone 2 (RARa) and clone 66 (PML-RAR), 
both of which cover the entire cDNA, was transferred to the pCMX 
expression vector (Umesono et al., 1991) which contains the cytomeg 
alovirus promoter. These plasmids were named pCMX RARa and 
pCMX PML-RAR, respectively. To delete the PML region from pCMX 
PML-RAR, we first introduced a Ncol site changing T at nucleotide 
1254 (Figure 5) to G and changed Ile to Met. The transactivation capac- 
ity of pCMX PML-RAR and this mutant (pCMX PML-RAR Ncol) was 
identical in CV-1 cells (data not shown). Because the translation start 
site of PML-RAR is a Ncol site (Figure 5) the fragment between the 
two Ncol restriction sites was removed from pCMX PML-RAR Ncol 
(pCMX APML-RAR). pCMX PML-RAR(L) was constructed by replac- 
ing the entire PML coding segment (Bglll-BstEll fragment) from pCMX 
PML-RARwith thatofpSGSfML-RAR(L),agiftfrom Drs.AnneDejean 
and Hugh de The. pCMX LUC (Umesono et al., 1991) which contains 
the coding sequence of luciferase, was used as a control. 
The reporter plasmid ASV-CAT was constructed by replacing the 
TK promoter in TK-CAT (Damm et al., 1969) with the Sphl-Hindlll 
fragment of the SV40 early promoter. Oligonucleotides coding for 
TREp(Umesonoetal., 1991)and6RE(6RE2)(Sucovetal., 1990)were 
reported previously. Each oligonucleotide was inserted at the unique 
Hindlll site upstream of the SV40 promoter (ASV-TREp-CAT and 
ASV+RE-CAT), and the identity of the inserted oligonucleotide was 
confirmed by sequencing. Only single response elements were used 
to avoid potential artifical responses following multimerization of the 
binding sites. RARj3(P)-CAT (a gift from Dr. Henry Sucov) contains 
about 600 bp of the promoter region of the mouse RARP gene (Sucov 
et al., 1990). TK+RE),-LUC and RARj3(5K)-LUC are gifts from Drs. 
Anne Dejean and Hugh de The (1990b). 
Cell Culture and Transfection 
CV-1 cells were maintained in DMEM supplemented with 10% 
charcoal-resin double-stripped calf serum. Hep G2 cells were grown 
in DMEM with 10% fetal bovine serum. K562 cells and HL-60 cells 
were grown in RPM1 1640 medium with 10% and 20% fetal bovine 
serum, respectively. CV-1 and Hep G2 cells were transfected by the 
calcium phosphate method (Graham and van der Eb, 1973; Kakizuka 
et al., 1990) with 0.5 ng of pCMX receptor plasmid, 1 ug of reporter 
CAT or LUC plasmid, and 5 ug of pRASj3GAL (Umesono and Evans, 
1969) or pCMX-6GAL as an internal control. The cells were transfected 
for 6 hr, and after the DNA precipitates were washed out, they were 
incubated for an additional 36 hr with or without 1 PM RA (Sigma). 
K562 and HL-60 cells were transfected using the Gene Pulser electro- 
poration apparatus (Bio-Rad). Cells were collected by centrifugation at 
600 x g for 5 min, washed twice with ice-cold opt-MEM (GIBCO), and 
suspended in opt-MEM. Samples (0.2 ml) of cell suspension (5-10 x 
108 cells/ml) were kept on ice and electroporated in a 0.4 cm cuvette, 
using 960 uF at 250 V with 1 ug of a pCMX receptor plasmid and 2 pg 
of a reporter CAT plasmid and 6 pg of pCMX-6GAL as an internal 
control. The samples were kept at room temperature for 20-40 min 
and then transferred to 10 ml of medium and incubated at 37’C. After 
3 hr, cells were split into two samples in 10 ml of medium and further 
incubated for 36 hr with or without 1 nM RA. Cell extracts were pre- 
pared for 6-galactosidase, LUC, and CAT assays as described (Ume- 
sono and Evans, 1969). 
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GenBank Accession Numbers 
The accession numbers are M73776 for PML-1 and M73779 for 
PML-RAR. 
Note Added in Proof 
A new member of the PML family, called bmi-7, has recently been 
identified (van Lohuizen et al., 1991, Cell 65, 737-752; Haupt et al., 
1991, Cell 65, 753-763) that functions as a putative oncogene in 
transgenic mice. bmi-7 is apparently activated by retroviral insertion 
and cooperates with myc in triggering B cell lymphoma. These results 
support the idea that perturbation of the PML transcriptional pathways 
by PML-RAR may contribute to leukemogenesis. 
